SCHEDULE 13G/A: RA Capital Management Discloses 7.0% Passive Stake in Urogen Pharma Ltd.
Beneficial Ownership Report
RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Urogen Pharma Ltd. as of March 31, 2025.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
- The filing reports beneficial ownership of 3,206,271 Ordinary Shares of Urogen Pharma Ltd.
- This ownership represents 7.0% of Urogen Pharma Ltd.'s outstanding Ordinary Shares.
- The percentage is calculated based on 46,107,451 Ordinary Shares outstanding as of April 23, 2025, as reported in Urogen Pharma's Annual Report on Form 10-K/A filed on April 30, 2025.
- RA Capital Healthcare Fund, L.P. directly holds the 3,206,271 Ordinary Shares.
- RA Capital Management, L.P. serves as the investment adviser for the Fund and has sole power to vote and dispose of the securities held by the Fund.
- Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P.
- The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of a passive ownership stake. While not directly positive or negative about the company's operations, the continued significant investment by a reputable healthcare fund like RA Capital Management can be viewed as a moderately positive signal of investor confidence.
Positives
- A significant 7.0% stake held by a specialized healthcare investment firm like RA Capital Management may signal investor confidence in Urogen Pharma Ltd.'s long-term prospects.
- The filing confirms a passive investment strategy, indicating no immediate intent to influence or change the control of the issuer.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Urogen Pharma Ltd.'s future performance or strategic direction, as it is a beneficial ownership report filed by an investor.
Industry Context
This filing pertains to Urogen Pharma Ltd., a company in the pharmaceutical/biotechnology sector. RA Capital Management is a prominent investment firm specializing in healthcare and life sciences, indicating their continued interest and investment in companies within this industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive investor's stake, which can influence market perception and potentially provide a degree of stability or confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-04-23 | Date as of which 46,107,451 Ordinary Shares of Urogen Pharma Ltd. were reported outstanding. |
| 2025-04-30 | Date Urogen Pharma Ltd. filed its Annual Report on Form 10-K/A with the SEC, reporting outstanding shares. |
| 2025-05-15 | Date of signing and filing of the Schedule 13G Amendment No. 3. |
Keywords
Urogen Pharma Ltd., RA Capital Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.